O	0	11	Prospective
O	12	18	double
O	19	24	blind
O	25	35	randomized
O	36	43	placebo
O	43	44	-
O	44	54	controlled
O	55	63	clinical
O	64	69	trial
O	70	72	of
O	73	76	the
B-intervention	77	85	pectoral
I-intervention	86	92	nerves
I-intervention	93	94	(
I-intervention	94	98	Pecs
I-intervention	98	99	)
I-intervention	100	105	block
I-intervention	106	110	type
I-intervention	111	113	II
O	113	114	.

O	115	118	The
O	119	122	aim
O	123	125	of
O	126	130	this
O	131	139	clinical
O	140	145	trial
O	146	149	was
O	150	152	to
O	153	157	test
O	158	161	the
O	162	172	hypothesis
O	173	180	whether
O	181	187	adding
O	188	191	the
O	192	200	pectoral
O	201	207	nerves
O	208	209	(
O	209	213	Pecs
O	213	214	)
O	215	220	block
O	221	225	type
O	226	228	II
O	229	231	to
O	232	235	the
O	236	246	anesthetic
O	247	256	procedure
O	257	264	reduces
O	265	271	opioid
O	272	283	consumption
O	284	290	during
O	291	294	and
O	295	300	after
O	301	307	breast
O	308	315	surgery
O	315	316	.

O	317	318	A
O	319	330	prospective
O	331	341	randomized
O	342	348	double
O	349	354	blind
O	355	362	placebo
O	362	363	-
O	363	373	controlled
O	374	379	study
O	379	380	.

O	381	382	A
O	383	392	secondary
O	393	401	hospital
O	401	402	.

B-total-participants	403	406	140
B-eligibility	407	413	breast
I-eligibility	414	420	cancer
I-eligibility	421	426	stage
I-eligibility	427	428	1
I-eligibility	428	429	-
I-eligibility	429	430	3
I-eligibility	431	439	patients
I-eligibility	440	450	undergoing
I-eligibility	451	461	mastectomy
I-eligibility	462	464	or
I-eligibility	465	476	tumorectomy
I-eligibility	477	481	with
I-eligibility	482	490	sentinel
I-eligibility	491	495	node
I-eligibility	496	498	or
I-eligibility	499	507	axillary
I-eligibility	508	512	node
I-eligibility	513	523	dissection
O	523	524	.

O	525	533	Patients
O	534	538	were
O	539	549	randomized
O	550	552	to
O	553	560	receive
O	561	567	either
O	568	569	a
O	570	574	Pecs
O	575	580	block
O	581	585	with
O	586	601	levobupivacaine
O	602	603	0
O	603	604	.
O	604	606	25
O	606	607	%
O	608	609	(
O	609	610	n
O	610	611	=
B-intervention-participants	611	613	70
O	613	614	)
O	615	617	or
B-control	618	625	placebo
O	626	631	block
O	632	636	with
O	637	643	saline
O	644	645	(
O	645	646	n
O	646	647	=
B-control-participants	647	649	70
O	649	650	)
O	650	651	.

O	652	655	The
O	656	660	pain
O	661	667	levels
O	668	672	were
O	673	682	evaluated
O	683	685	by
O	686	693	Numeric
O	694	700	Rating
O	701	706	Scale
O	707	708	(
O	708	711	NRS
O	711	712	)
O	713	717	pain
O	718	724	scores
O	725	727	at
O	728	730	15
O	730	731	-
O	731	737	minute
O	738	747	intervals
O	748	754	during
O	755	758	the
O	759	763	post
O	764	774	anesthesia
O	775	779	care
O	780	784	unit
O	785	789	stay
O	790	794	time
O	795	796	(
O	796	800	PACU
O	800	801	)
O	801	802	,
O	803	805	at
O	806	807	2
O	807	808	-
O	808	812	hour
O	813	822	intervals
O	823	826	for
O	827	830	the
O	831	836	first
O	837	840	24h
O	841	843	on
O	844	847	the
O	848	852	ward
O	853	856	and
O	857	859	at
O	860	861	4
O	861	862	-
O	862	866	hour
O	867	876	intervals
O	877	880	for
O	881	884	the
O	885	889	next
O	890	893	24h
O	893	894	.

O	895	909	Intraoperative
O	910	913	and
O	914	927	postoperative
O	928	934	opioid
O	935	946	consumption
O	947	951	were
O	952	960	recorded
O	961	967	during
O	968	971	the
O	972	976	full
O	977	981	stay
O	981	982	.

O	983	990	Patient
O	991	1003	satisfaction
O	1004	1007	was
O	1008	1017	evaluated
O	1018	1022	upon
O	1023	1032	discharge
O	1033	1038	using
O	1039	1040	a
O	1041	1043	10
O	1043	1044	-
O	1044	1049	point
O	1050	1055	scale
O	1055	1056	.

B-outcome	1057	1071	Intraoperative
I-outcome	1072	1082	sufentanil
I-outcome	1083	1095	requirements
O	1096	1100	were
O	1101	1111	comparable
O	1112	1115	for
O	1116	1119	the
O	1120	1124	Pecs
O	1125	1128	and
O	1129	1136	placebo
O	1137	1142	group
O	1143	1144	(
B-iv-cont-mean	1144	1145	8
I-iv-cont-mean	1145	1146	.
I-iv-cont-mean	1146	1147	0
O	1147	1148	±
B-iv-cont-sd	1148	1149	3
I-iv-cont-sd	1149	1150	.
I-iv-cont-sd	1150	1151	5
I-iv-cont-sd	1151	1152	μ
I-iv-cont-sd	1152	1153	g
O	1154	1157	and
B-cv-cont-mean	1158	1159	7
I-cv-cont-mean	1159	1160	.
I-cv-cont-mean	1160	1161	8
O	1161	1162	±
B-cv-cont-sd	1162	1163	3
I-cv-cont-sd	1163	1164	.
I-cv-cont-sd	1164	1165	0
I-cv-cont-sd	1165	1166	μ
I-cv-cont-sd	1166	1167	g
O	1167	1168	,
O	1169	1170	P
O	1170	1171	=
O	1171	1172	0
O	1172	1173	.
O	1173	1176	730
O	1176	1177	)
O	1177	1178	.

O	1179	1187	Patients
O	1188	1190	in
O	1191	1194	the
O	1195	1199	Pecs
O	1200	1205	group
O	1206	1217	experienced
O	1218	1231	significantly
O	1232	1236	less
B-outcome	1237	1241	pain
O	1242	1246	than
O	1247	1255	patients
O	1256	1258	in
O	1259	1262	the
O	1263	1270	control
O	1271	1276	group
O	1277	1278	(
O	1278	1279	P
O	1279	1280	=
O	1280	1281	0
O	1281	1282	.
O	1282	1285	048
O	1285	1286	)
O	1287	1293	during
O	1294	1299	their
O	1300	1304	PACU
O	1305	1309	stay
O	1309	1310	.

O	1311	1322	Furthermore
O	1322	1323	,
O	1324	1332	patients
O	1333	1335	in
O	1336	1339	the
O	1340	1344	Pecs
O	1345	1350	group
O	1351	1359	required
O	1360	1371	significant
O	1372	1376	less
B-outcome	1377	1390	postoperative
I-outcome	1391	1398	opioids
O	1399	1400	(
B-iv-cont-mean	1400	1401	9
I-iv-cont-mean	1401	1402	.
I-iv-cont-mean	1402	1404	16
O	1404	1405	±
B-iv-cont-sd	1405	1407	10
I-iv-cont-sd	1407	1408	.
I-iv-cont-sd	1408	1412	15mg
O	1413	1416	and
B-cv-cont-mean	1417	1419	14
I-cv-cont-mean	1419	1420	.
I-cv-cont-mean	1420	1422	97
O	1422	1423	±
B-cv-cont-sd	1423	1425	14
I-cv-cont-sd	1425	1426	.
I-cv-cont-sd	1426	1430	38mg
O	1431	1439	morphine
O	1440	1450	equivalent
O	1450	1451	,
O	1452	1453	P
O	1453	1454	=
O	1454	1455	0
O	1455	1456	.
O	1456	1459	037
O	1459	1460	)
O	1461	1464	and
O	1465	1473	required
O	1474	1485	significant
O	1486	1491	fewer
B-outcome	1492	1504	postsurgical
I-outcome	1505	1511	opioid
I-outcome	1512	1526	administration
O	1527	1540	interventions
O	1541	1545	than
O	1546	1554	patients
O	1555	1557	in
O	1558	1561	the
O	1562	1569	control
O	1570	1575	group
O	1576	1577	(
O	1577	1578	P
O	1578	1579	=
O	1579	1580	0
O	1580	1581	.
O	1581	1584	045
O	1584	1585	)
O	1585	1586	.

O	1587	1591	Both
O	1592	1599	patient
O	1599	1600	-
O	1600	1606	groups
O	1607	1611	were
O	1612	1616	very
B-outcome	1617	1626	satisfied
O	1627	1632	about
O	1633	1638	their
O	1639	1649	management
O	1650	1651	(
B-iv-cont-mean	1651	1652	9
I-iv-cont-mean	1652	1653	.
I-iv-cont-mean	1653	1654	6
O	1654	1655	±
B-iv-cont-sd	1655	1656	0
I-iv-cont-sd	1656	1657	.
I-iv-cont-sd	1657	1658	6
O	1659	1662	and
B-cv-cont-mean	1663	1664	9
I-cv-cont-mean	1664	1665	.
I-cv-cont-mean	1665	1666	1
O	1666	1667	±
B-cv-cont-sd	1667	1668	1
I-cv-cont-sd	1668	1669	.
I-cv-cont-sd	1669	1670	8
O	1671	1673	on
O	1674	1675	a
O	1676	1678	10
O	1678	1679	-
O	1679	1684	point
O	1685	1690	scale
O	1690	1691	,
O	1692	1693	P
O	1693	1694	=
O	1694	1695	0
O	1695	1696	.
O	1696	1699	211
O	1699	1700	)
O	1700	1701	.

O	1702	1705	The
O	1706	1710	Pecs
O	1711	1716	block
O	1717	1724	reduces
O	1725	1737	postsurgical
O	1738	1744	opioid
O	1745	1756	consumption
O	1757	1763	during
O	1764	1767	the
O	1768	1772	PACU
O	1773	1777	stay
O	1778	1782	time
O	1783	1786	for
O	1787	1795	patients
O	1796	1806	undergoing
O	1807	1813	breast
O	1814	1821	surgery
O	1821	1822	.
